Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2012

View Archived Issues

Polypeptide confers neuroprotection after stroke

New E-NPP 2 inhibitors patented by Ono Pharmaceutical

Actelion Pharmceuticals discloses novel prostanoid DP2 receptor antagonists

U.K. universities present new dust mite peptidase 1 inhibitors

Sanofi synthesizes new fibroblast growth factor receptor antagonists

New nematode serpin-based thrombin inhibitors discovered

Third arGEN-X candidate therapeutic advances into preclinical development

Astrogenetix and NASA enter agreement for drug research in space

Eribulin mesilate added to chemotherapy in patients with bladder cancer

VistaGen Therapeutics and Cato enter drug rescue agreement

Bayer and Almirall to copromote oral anticoagulant in Spain

AVI BioPharma reports data from phase I trials of AVI-6002 and AVI-6003

DMC recommends LibiGel safety study continue as planned

Titan Pharmaceuticals reports results from probuphine trial

Potassium channel antagonist improves motor function in model of stroke

Gene therapy succesfully readministered to patients with Leber's congenital amaurosis

Jubilant and Endo Pharmaceuticals nominate anticancer candidate

Tekmira Ebola fever therapy enters clinic

GlobeImmune begins phase I trial of new cancer vaccine

Pfizer and ICAgen identify new candidate analgesics

Metal-dependent inhibitors of LDL-PLA2 identified

Outcome of FDA advisory committee meeting on Qutenza sNDA reported

Vernalis and Tris Pharma enter licensing agreement

Genmab achieves second milestone in CNS disorder collaboration

Phase I trial of Patrys anticancer antibody meets primary endpoint

FDA advisory committee issues vote on Dacogen sNDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...